Biotech Stocks

Cellares links with GenomeFrontier to test automation approach for virus-free CAR-Ts

FiercePharma 1h ago

Cellares is partnering with Taiwanese biotech GenomeFrontier Therapeutics to evaluate the integrated contract developer and manufacturer’s cell shuttle platform for use in the production of virus-free CAR-T therapies.

Discussion

Sign in to join the discussion. Comments loading…